<DOC>
	<DOC>NCT01561963</DOC>
	<brief_summary>The purpose of this study is to evaluate how the pharmacokinetics of apremilast may be affected by a single intravenous dose of rifampin and multiple oral doses of rifampin.</brief_summary>
	<brief_title>A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>Healthy male or female subjects of any ethnic origin between ages of 18 and 55 with a body mass index between 18 and 33 Recent history (i.e., within 3 years) of any clinically significant neurological, gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, endocrine, hematological, dermatological, psychological, allergic or other major disorders. Use of any prescribed or nonprescribed systemic or topical medication (including vitamins and herbal medicines, e.g. St. John's Wort) within 30 days of the first dose, unless an exception is granted by the sponsor. Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial. Exposure to an investigational drug (new chemical entity) within 30 days prior to the first dose administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Apremilast</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>